Open-label trial to investigate the effect of Rifampicin on prevention of recurrence in patients after radical treatment of primary hepatocellular carcinoma

Trial Profile

Open-label trial to investigate the effect of Rifampicin on prevention of recurrence in patients after radical treatment of primary hepatocellular carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Rifampicin (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors GeneCare Research Institute
  • Most Recent Events

    • 19 Apr 2017 Status changed from recruiting to completed.
    • 16 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top